ArticleImmunity2020
Signaling through the Inhibitory Fc Receptor FcγRIIB Induces CD8
Open access · bronzeAbstract read
In one paragraph
Article in Immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 115 citations in OpenAlex.
- Distinct peripheral blood molecular signature emerges with successful tacrolimus withdrawal in kidney transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Trial
- AFF3 maintains metabolic quiescence in naive CD8 T cells and prevents premature immune aging.JCI insight · 2026Article
- Virtual memory CD8⁺ T cells in aging: heterogeneity, bystander protection, inflammatory potential, and inhibitory regulation.Immunity & ageing : I & A · 2026Review
- Tumor-Derived Exosomes Deliver Membrane-Bound Fgl2 to Activate FcγRIIB-Mediated Immunosuppression in Myeloid-Derived Suppressor Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Spatiotemporal Transcriptomics Characterizes Immune Microenvironment During Mouse Liver Aging.Aging cell · 2026Article
- The unseen architects of metastasis: coagulation factors in pre-metastatic niche development.Cell communication and signaling : CCS · 2026Review
- Disruption of FGL2 induces TFEB-dependent lysosomal degradation of PD-L1 and enhances the efficacy of anti-PD1 therapy in hepatocellular carcinoma.Cell communication and signaling : CCS · 2026Article
- Induction of neurodegeneration in the hippocampus of senescence-accelerated mouse-prone 8 (SAMP8) mice by blood-brain barrier-crossing serum amyloid P component.Journal of neuroinflammation · 2026Article
- A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy.Frontiers in immunology · 2026Article
- Radioresistant intrathymic stem cells: retrospective analysis and concept of the role in thymic oncogenesis and post-irradiation regeneration.Frontiers in immunology · 2026Review
- Article
- sFGL2 as a Potential Immunosuppressive Biomarker Associated With COVID-19 Severity in Kidney Transplant Recipients.Immunity, inflammation and disease · 2025Article
- FcγRIIIa is a noncanonical costimulatory molecule for CD8 T cells.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Protective role of anti-SARS-CoV-2 antibody responses against vital organ related long COVID symptoms.Scientific reports · 2025Article
- Fgl2 regulates FcγRIIB+CD8+ T cell responses during infection.JCI insight · 2025Article
- Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma.JCI insight · 2025Article
- A Comprehensive Review of Fc Gamma Receptors and Their Role in Systemic Lupus Erythematosus.International journal of molecular sciences · 2025Review
- Exploring the predictive "psycho-biomarkers" for checkpoint immunotherapy in cancer.Frontiers in immunology · 2025Article
- Bioinformatics Analysis of Programmed Death-1-Trastuzumab Resistance Regulatory Networks in Breast Cancer Cells.Asian Pacific journal of cancer prevention : APJCP · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 2 countries.
Anna B MorrisDepartment of Surgery, Emory University, Atlanta, GA, USA.
Clara R FarleyDepartment of Surgery, Emory University, Atlanta, GA, USA.
David F PinelliDepartment of Surgery, Emory University, Atlanta, GA, USA.
Layne E AdamsDepartment of Surgery, Emory University, Atlanta, GA, USA.
Mark S CraggAntibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
Jeremy M BossDepartment of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
Christopher D ScharerDepartment of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
Miguel FribourgTranslational Transplant Research Center and the Precision Institute of Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Paolo CravediTranslational Transplant Research Center and the Precision Institute of Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Peter S HeegerTranslational Transplant Research Center and the Precision Institute of Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mandy L FordDepartment of Surgery, Emory University, Atlanta, GA, USA. Electronic address: mandy.ford@emory.edu.
Emory University · USIcahn School of Medicine at Mount Sinai · USUniversity of Southampton · GB
Funding
Noninvasive Markers and Transplant Outcome in HumansU01AI063594 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEEGER, PETER SCOTT · 2004 to 2022
$66.5MPREDOCTORAL TRAINING PROGRAM IN GENETICST32GM008490 · NIGMS · EMORY UNIVERSITY · PI BOSS, JEREMY M. · 1993 to 2022
$8.0MRegulation of PD-1 gene expressionR01AI113021 · NIAID · EMORY UNIVERSITY · PI BOSS, JEREMY M. · 2014 to 2024
$4.7MDeterminants of T Cell Fate in Transplantation ToleranceR01AI073707 · NIAID · EMORY UNIVERSITY · PI FORD, MANDY L · 2008 to 2021
$4.0MAdvanced Research Training in Transplantation ScienceT32AI070081 · NIAID · EMORY UNIVERSITY · PI Mandy L Ford · 2006 to 2026
$3.1MCostimulatory and Coinhibitory Receptor Control of Alloreactive T Cell ResponsesR01AI104699 · NIAID · EMORY UNIVERSITY · PI FORD, MANDY L · 2013 to 2017
$2.1MCancer Research UK 20537Cancer Research UK 24721NIAID NIH HHS R01 AI073707NIAID NIH HHS R01 AI104699NIAID NIH HHS R01 AI113021NIAID NIH HHS T32 AI070081NIAID NIH HHS U01 AI063594NIGMS NIH HHS T32 GM008490
Abstract
Effector CD8
Indexed as
AdultAgedAnimalsApoptosisCaspase 3Caspase 7CD8-Positive T-LymphocytesCell Line, TumorFemaleFibrinogenGraft RejectionHumansImmunoglobulin GImmunosuppression TherapyMaleMelanoma, ExperimentalCASP3 protein, humanCASP7 protein, humanCaspase 3Caspase 7FCGR2B protein, humanFGL2 protein, humanFibrinogenImmunoglobulin GReceptors, IgGapoptosisCD8(+) T cellsFcgRIIBFgl2transplantationtumor immunology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.